May 29 (WARYATV) – Projections for annual global sales of weight-loss drugs have skyrocketed to approximately $150 billion by the early 2030s, driven by increasing supply, potential for wider usage, and a growing number of competitors. This marks a significant leap from the $100 billion range estimated just a year ago.
The surge in demand for weight-loss treatments from pharmaceutical giants Novo Nordisk (NOVOb.CO) and Eli Lilly (LLY.N) has been a major factor in this upward revision. These companies are ramping up production to meet the needs of millions of people seeking effective weight-loss solutions.
Michael Kleinrock, senior research director at healthcare analytics firm IQVIA Institute for Data Science, commented on the phenomenon, stating, “It is very unusual to have a medicine that is capturing the imagination of millions of people.”
The burgeoning market for weight-loss drugs reflects a broader shift in public interest and acceptance of pharmaceutical interventions for weight management, spurring increased competition and innovation in the field. As supply chains strengthen and new entrants vie for market share, the industry is poised for unprecedented growth in the coming decade.
